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ABSTRACT
Background: Nebulized drugs for asthma treatment are often mixed together in order to simplify inhalation
regimens, although not recommended. We therefore evaluated aerosol characteristics and physicochemical
stability of the admixture of an inhaled corticosteroid suspension with a beta2-agonist solution.
Methods: An 8-stage cascade impactor was used to measure the particle size distribution of admixture of Pul-
micortⓇ RespulesⓇ (budesonide, 0.5 mg2 mL) with MeptinⓇ Inhalation Solution Unit (procaterol hydrochlo-
ride, 30 μg0.3 mL) from a jet nebulizer, PARI LC PlusⓇ. Concentration of each drug was assayed with high-
pressure liquid chromatography. Physicochemical compatibility was also assessed up to 24 hours after mixing.
Results: With regard to budesonide, impactor parameters such as mass median aerodynamic diameter
(MMAD) and respirable mass (RM) were comparable between admixtures and single-drug preparations (2.92 ±
0.03 vs 2.99 ± 0.14 μm, 146.8 ± 2.9 vs 147.6 ± 8.2 μg, respectively). On the other hand, delivery rates of pro-
caterol increased when admixed with budesonide suspension, resulting in significantly higher RM (15.1 ± 0.8
vs 10.2 ± 0.5 μg, p < 0.01). Variations from initial concentration in the percentages of drug remaining at any
time point were less than 10%, and there were no appreciable changes in pH of the admixtures for up to 24
hours.
Conclusions: There is a possibility that admixture might influence of aerodynamic characteristics of pro-
caterol, but not budesonide. In vivo data will be needed for the clinical implications of our findings.
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INTRODUCTION
Nebulizers are widely used for the inhalation of drugs
in a variety of respiratory diseases such as asthma.
The efficacy of inhalation therapy using a nebulizer is
influenced by a number of factors, including the de-
sign of the device and the characteristics of the drug
solution.1 When patients need several kinds of nebu-
lized drugs, a substantial proportion of them might
admix medications, because nebulization is a time-
consuming task, even if the effect of co-
administration on aerosol output and bioactivity are
poorly studied. Indeed, one survey of patients with
cystic fibrosis showed that a quarter of them reported
mixing of medications.2
Inhaled corticosteroids (ICS) are the first line ther-
apy for children with persistent asthma, because
asthma is characterized by chronic inflammation of
the airways.3 Budesonide inhalation suspension (BIS)
is one of the ICSs available for nebulization, and clini-
cal studies demonstrated its efficacy and safety in the
long-term management of young children with
asthma.4-6 Furthermore, BIS has been reported to be
useful for the treatment of acute episodes of asthma.7
In addition to ICS, a beta2-agonist is another impor-
tant medicine, which has been used not only as a re-
liever but also as a controller. A recent study showed
the efficacy of a regimen using a budesonidefor-
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moterol dry-powder inhaler for both maintenance and
as-needed symptom relief in older children with
asthma.8 For younger children, nebulization is prefer-
able to a meter-dosed or dry-powder inhaler. Furusho
showed that regular inhalation of the combination of
nebulized sodium cromoglycate and a beta2-agonist,
salbutamol was superior to either cromoglycate alone
or salbutamol alone for the treatment of moderate-to-
severe asthma in children.9 Thus, a beta2-agonist
might be added to BIS as a single nebulization for-
mula, and a couple of clinical studies had been done
using an admixture of BIS and a beta2-agonist.10,11
However, systemic evaluations regarding the effect of
co-administration of these drugs on physicochemical
stability are limited,12 and there has been no study
which looked into the effect of the admixture on aero-
sol characteristics of each drug. Therefore, we con-
ducted an in vitro study, using a combination of BIS
and a beta2-agonist, procaterol. Procaterol is a selec-
tive and full beta2-agonist, which has been shown to
elicit anti-inflammatory effects on eosinophils in com-
bination with inhaled corticosteroids in vitro.13,14
METHODS
DRUGS AND NEBULIZER
BIS, PulmicortⓇ RespulesⓇ 0.5 mg2 mL (Astra-
Zeneca, KK, Osaka, Japan) and a beta2-agonist, pro-
caterol inhalation solution, MeptinⓇ Inhalation Solu-
tion Unit 30 μg0.3 mL (Otsuka Pharmaceutical, To-
kyo, Japan) were used in this study. The following
formulas were prepared: 2 mL BIS combined with 0.3
mL saline (0.9% NaCl), 2 mL saline combined with 0.3
mL procaterol solution, and 2 mL BIS combined with
0.3 mL procaterol solution. These preparations were
nebulized via a PARI LC PlusⓇ nebulizer (PARI
GmbH, Starnberg, Germany) driven by a PARI Tur-
boBoy NⓇ compressor (PARI GmbH).
MEASURING AEROSOL CHARACTERISTICS
To measure delivery rates, a nebulizer was held in
upright position by a ring stand and was connected
with a tube to a glass bottle. Aerosol droplets of the
prepared medications were collected during continu-
ous nebulization, and the concentration of each drug
was assayed with high-pressure liquid chromatogra-
phy (HPLC LC-2010CHT, Shimadzu, Kyoto, Japan).
Delivery rates were calculated as percentages of
nominal dose.
Particle size distribution of each drug was analyzed
with an 8-stage cascade impactor (Anderson Cascade
Impactor, Coply Scientific, Nottingham, UK). Aerosol
droplets were collected in the impactor at a flow rate
of 28.3 Lmin with the corresponding cut-off points;
0.4, 0.7, 1.1, 2.1, 3.3, 4.7, 5.8, and 9.0 μm. Each stage
of the impactor was washed with a solvent and the
concentration of each drug in the solvent was assayed
with HPLC. Mass median aerodynamic diameter
(MMAD) and geometric standard deviation (GSD),
respirable fraction (RF; percent of particles in the 0.4-
5 μm range), and respirable mass (RM; total drug
output x RF) were calculated, according to the Euro-
pean Pharmacopoeial method.
STABILITY ASSESSMENTS
Prepared admixtures were stored in a 10-ml glass test
tube at room temperature under scattered light. Sta-
bility of each preparation was assessed 1, 2, 4, 8, and
24 hours after admixture. Concentrations of drugs
were assayed as mentioned above, and pH values of
the admixtures were obtained with a pH meter (F-22,
HORIBA, Ltd., Kyoto, Japan).
STATISTICAL ANALYSIS
Each test was performed three times. Comparisons of
aerosol characteristics between the prepared medica-
tions were tested using an independent-sample t-test.
Statistical significance was assumed to be p < 0.05.
RESULTS
AEROSOL CHARACTERISTICS
The addition of procaterol solution to BIS did not af-
fect the delivery rate of budesonide (Fig. 1). Impac-
tion analysis also revealed no differences in aerosol
particle size distribution of budesonide between the
admixtures and single-drug preparations (Fig. 2a).
Calculated impactor parameters regarding budeson-
ide were also comparable between the admixtures
and single-drug preparations (Table 1). On the other
hand, significantly higher amount of procaterol was
delivered when admixed with BIS compared with
single-drug preparations (p < 0.01, Fig. 1). Impaction
analysis showed that distribution rates of procaterol
were increased in smaller particle size (Fig. 2b), re-
sulted in significantly higher RM in the admixtures (p
< 0.01, Table 2).
STABILITY
Variations from initial concentration in the percent-
ages of drug remaining at any time point were less
than 10%, and there were no appreciable changes in
pH of the admixtures during 24 hours (Table 3).
DISCUSSION
Although BIS has been used clinically in admixtures
with beta2-agonists,10,11 systemic evaluations regard-
ing the effect of admixtures on the aerosol character-
istics and physicochemical stability are limited. Be-
cause of the differences in physical characteristics be-
tween suspension (BIS) and solution (procaterol),1
there is a possibility that admixing these drugs could
have some effect on the aerosol characteristics and
physicochemical compatibility of them. With regard
to budesonide, we did not find any evidence that addi-
tion of procaterol solution to BIS altered delivery rate
and aerosol particle size distribution of budesonide.
Reid et al. showed that treatment with the combina-
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Fig.　1　Delivery rates of budesonide and procaterol from admixtures or single-drug 
preparations. Results are shown as mean + SD (n = 3). *p < 0.01 by t-test (compari-
son of procaterol alone against admixture).
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Fig.　2　Effect of admixture on particle size distributions of budesonide (a) and procaterol (b). Results are 
shown as mean ± SD (n = 3). *p < 0.05, **p < 0.01, and ***p < 0.001 by t-test (comparison of admixtures 
against single-drug preparations). Abbreviation: IP, induction port.
D
is
tr
ib
ut
io
n 
ra
te
 (
%
)
D
is
tr
ib
ut
io
n 
ra
te
 (
%
)
Particle size
IP
>9
.0
 Pm
<9
.0
 Pm
<5
.8
 Pm
<4
.7
 Pm
<3
.3
 Pm
<2
.1
 Pm
<1
.1
 Pm
<0
.7
 Pm
<0
.4
 Pm I
P
>9
.0
 Pm
<9
.0
 Pm
<5
.8
 Pm
<4
.7
 Pm
<3
.3
 Pm
<2
.1
 Pm
<1
.1
 Pm
<0
.7
 Pm
<0
.4
 Pm
Admixture
Alone
Admixture
Alone
30
25
20
15
10
5
0
30
25
20
15
10
5
0
Particle size
a b
*
**
***
*
tion of BIS plus beta2-agonists (terbutaline or salbuta-
mol) for longer than 6 months did not have a signifi-
cant impact on linear growth in asthmatic children
younger than 3 years old.10 Although they did not
have a treatment arm consisting of children who were
treated with BIS alone, our results suggest that the
admixture itself could not adversely affect linear
growth. Furthermore, the admixture had no effect on
the stability of budesonide, consistent with the previ-
ous study that found chemical compatibility of
budesonide inhalation solution for up to 30 min with
commonly used nebulized medications such as al-
buterol, cromolyn, and ipratropium.12
In contrast to budesonide, delivery rate of pro-
caterol significantly increased in a combination with
BIS, resulting in higher RM of procaterol. There is
one possibility that Polysolvate 80, a nonionic surfac-
tant contained in BIS, might cause this change.
These results lead to concern about whether higher
dose of beta2-agonist might cause adverse effects.
We previously evaluated whether differences in nebu-
lizer performance could influence safety and efficacy
of inhaled beta2-agonist in children with asthma, us-
ing two different types of nebulizers with a two-fold
difference in their delivery rates.15 Contrary to our as-
sumption, no adverse effects were found in all the
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Table　1　Aerosol characteristics of budesonide
Preparation MMAD (μm) GSD RF (%) RM (μg)
BIS + Saline 2.99 ± 0.14 2.12 ± 0.02 74.9 ± 2.1 142.7 ± 9.1
BIS + Procaterol 2.92 ± 0.03 2.14 ± 0.00 75.5 ± 0.4 141.9 ± 3.8
Results are shown as mean ± SD (n = 3).
Abbreviations: BIS, budesonide inhalation suspension; MMAD, mass median aerodynamic diameter; GSD, geometric standard deviation; 
RF, respirable fraction; RM, respirable mass.
Table　2　Aerosol characteristics of procaterol
Preparation MMAD (μm) GSD RF (%) RM (μg)
Procaterol + saline 1.56 ± 0.15 2.15 ± 0.07 89.6 ± 2.1 10.2 ± 0.5
Procaterol + BIS 1.69 ± 0.04 2.23 ± 0.09 87.6 ± 2.0   15.1 ± 0.8*
*p < 0.01 by t-test (comparison of procaterol alone against admixture).
Results are shown as mean ± SD (n = 3).
Abbreviations: BIS, budesonide inhalation suspension; MMAD, mass median aerodynamic diameter; GSD, geometric standard deviation; 
RF, respirable fraction; RM, respirable mass.
Table　3　Physicochemical compatibility of the admixture of budesonide inhalation suspension and procaterol
a) Recovery rates (%)
1 2 4 8 24 (hr)
Budesonide  96.2 ± 2.4  93.0 ± 6.6  96.4 ± 0.4 96.5 ± 0.3  96.8 ± 1.1
Procaterol 101.1 ± 3.8 101.5 ± 2.8 102.0 ± 6.5 98.5 ± 1.4 101.5 ± 0.8
b) Changes in pH
pre 1 2 4 8 24 (hr)
Budesonide 4.5 ± 0.0
4.0 ± 0.0 4.0 ± 0.0 4.1 ± 0.0 4.1 ± 0.0 4.1 ± 0.0
Procaterol 3.5 ± 0.0
Results are shown as mean ± SD (n = 3).
subjects, and efficacy was comparable between the
subjects who inhaled with either nebulizers. To date,
no controlled study has been undertaken to deter-
mine the optimal dose of inhaled beta2-agnoist for the
treatment of children with asthma. Therefore, it is dif-
ficult to say that high RM of procaterol in this study
would increase the frequency or extent of the adverse
effects.
In this study, we showed a possibility that admix-
ture of BIS and procaterol solution might affect aero-
dynamic characteristics of procaterol, but not
budesonide. To address the question whether these
in vitro findings are clinically relevant or not, further
clinical studies are needed in terms of efficacy and
safety of the combination treatment with nebulized
ICS and beta2-agonist.
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